Funding Freeze Under Trump Administration Stalls Critical HIV Vaccine Research in Africa

In a revealing interview, Glenda Gray, the program director of a prominent research consortium, detailed the significant setbacks faced by an HIV vaccine trial and other related research initiatives in Africa due to a funding freeze implemented by the Trump administration.

Gray explained that the suspension of financial support from USAID has directly impacted the progress of developing an effective HIV vaccine on the continent, where millions continue to suffer from the epidemic. The halt not only slows down scientific advancements but also affects numerous lives dependent on breakthroughs in HIV research.

The full implications of this funding freeze are still unfolding, and researchers like Gray are calling for urgent action to resume financial aid and support to continue their critical work. 

Date: February 26, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation Breakthrough at La Trobe University: Killer T Cells May Be the Future of Bird Flu Vaccination What the PlayStation Network Outage Can Teach the Biotech Industry GLP-1 Weight Loss Drugs Might Cause Blindness

Author

Mark Chiang

Ph.D in Biomedical Informatics Head of AI at GeneOnline